MARKET WIRE NEWS

Visionary Holdings Signs Cooperation Agreement with Strategic Investment Partner for Proposed US$20 Million Investment in Qingdao Anti-Aging Project

MWN-AI** Summary

Visionary Holdings Inc. (NASDAQ: GV), a technology-driven healthcare enterprise based in Toronto, has announced a significant strategic initiative aimed at establishing an anti-aging project in Qingdao, China. On March 31, 2026, the company signed an Investment Cooperation Agreement with Qingdao Xihai Rongke Enterprise Operation Management Co., Ltd., targeting a proposed investment of US$20 million. This partnership will facilitate the creation of a project company responsible for launching the "GV China Anti-Aging Research Center" in Qingdao's West Coast New Area.

The initiative aims to prioritize research and development focusing on cell therapy and biologics, while also establishing a chain model for the "GV Anti-Aging Health Management Center" within the Shandong market, ensuring alignment with international product and service standards. The investment will be executed in two phases, with the initial phase contingent on meeting specific milestones, including the establishment of the project company and the opening of the flagship center.

Moreover, the cooperation framework outlines additional support measures that will provide comprehensive assistance, including local resource coordination, preferential office space, talent housing support, and aid with regulatory approvals. Visionary’s CEO, Xiyong Hou, emphasized that this agreement establishes a definitive structure for the project, setting the stage for operational efficiency.

The anticipated timeline for financial execution hinges on finalizing the definitive agreements and the fulfillment of customary closing conditions. As Visionary moves forward, further updates regarding the project’s development, including capital arrangements and operational launches, are expected to be communicated to stakeholders in alignment with legal and disclosure requirements. Overall, this venture represents a significant step in Visionary’s commitment to technological advancement and health innovation on a global scale.

MWN-AI** Analysis

Visionary Holdings Inc. (NASDAQ: GV) has made a strategic move by entering into a significant cooperation agreement for a proposed $20 million investment in its Qingdao anti-aging project. This partnership with Qingdao Xihai Rongke positions Visionary to capitalize on the burgeoning health and wellness industry, particularly in China, where the demand for anti-aging solutions is accelerating.

Market analysts see this as a pivotal opportunity that could enhance Visionary’s portfolio and drive future revenue growth. With the establishment of the GV China Anti-Aging Research Center and a chain model for the GV Anti-Aging Health Management Center, the company is poised to leverage its technological edge and competitive advantage in the AI healthcare space. Phase-based funding structured around tangible milestones ensures that capital allocation is directly linked to performance outcomes, reducing risk exposure for investors.

Moreover, the anticipated development of a Sino-U.S. international life sciences incubator could attract additional partnerships and investments, further fortifying Visionary’s market position in the global healthcare landscape. The explicit timeline for achieving profitability within one year of the flagship center's opening presents a compelling case for investors, highlighting the project’s potential to generate cash flow relatively swiftly.

Investors should remain cognizant of the speculative aspects of Visionary’s forward-looking statements. The success of this venture depends on further definitive agreements, local regulatory approvals, and effective execution against set milestones. Given these variables, while the initial outlook appears promising, vigilance is essential.

In conclusion, for those considering investment in Visionary Holdings, the proposed $20 million investment presents an attractive opportunity, but due diligence is recommended to navigate the inherent risks associated with such an ambitious project.

**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.

Source: GlobeNewswire

TORONTO, March 31, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (NASDAQ: GV) (“Visionary” or the “Company”) today announced that it has entered into an Investment Cooperation Agreement with Qingdao Xihai Rongke Enterprise Operation Management Co., Ltd. in connection with a proposed US$20 million strategic investment for the Company’s Qingdao anti-aging project in Qingdao West Coast New Area, China.

Under the agreement, the parties plan to establish a project company to serve as the operating entity for the collaboration. The project company is expected to establish the “GV China Anti-Aging Research Center” in Qingdao West Coast New Area, with an initial focus on research and translational development in areas including cell therapy and biologics. In parallel, the project company is also expected to begin building out a “GV Anti-Aging Health Management Center” chain model in China, initially with a focus on the Shandong market and with the goal of introducing internationally aligned products and service standards.

According to the cooperation framework, the investor intends to make a total investment of no less than US$20 million into the project company in two phases. The initial phase is structured around three milestone-based payments: 30% upon establishment of the project company and opening of its capital account, 40% upon completion of renovation of the research center and installation of equipment, and the final 30% after the first flagship center opens and generates its first month of operating data. A second-phase investment of US$10 million is contemplated subject to the Company’s subsequent development progress.

In addition to the proposed investment, the agreement provides for a range of implementation-related support measures, including coordination of local resources in Qingdao West Coast New Area, provision of preferential office and R&D space, talent housing support, assistance with business registration, foreign investment filings, environmental review, and healthcare-related qualification approvals, as well as joint development of a Sino-U.S. international life sciences incubator intended to attract upstream and downstream participants.

The agreement also outlines an initial investment framework for valuation and ownership. Based on the parties’ preliminary understanding, the project company’s pre-investment valuation is expected to be determined with reference to the value of the Company’s contributed intellectual property and cash capital, and, following the initial US$10 million phase of investment, the investor’s equity interest is currently contemplated on a preliminary basis, with final ownership percentages to be determined in definitive transaction documents following appraisal and due diligence.

The project company is also expected to operate with exclusive and lawful technology authorization, with core management and technical personnel to be designated to support ongoing operations. The agreement also references operating and development targets, including the goal of achieving profitability for the first anti-aging center within one year following completion of the investment and the pursuit of a leading market position within two years.

Xiyong Hou, Chief Executive Officer of Visionary, stated:

“We believe this agreement provides a defined framework for the proposed project, including a contemplated project vehicle, a phased funding structure, implementation milestones, regional support measures, and a basis for subsequent definitive documentation. We intend to continue advancing the formal investment agreement and shareholder agreement and move the project toward operational implementation as efficiently as possible. The timing of any initial financing remains subject to the execution of definitive agreements and the satisfaction of customary closing conditions.”

The Company further noted that progress under the proposed cooperation will depend on subsequent definitive agreements, establishment of the project company, capital arrangements, and implementation milestones. Subject to applicable law and disclosure requirements, the Company intends to provide further updates regarding definitive agreements, establishment of the project company, first-phase capital arrangements, construction of the research center, and launch of the first operating site as and when material developments occur.

About Visionary Holdings Inc.
Visionary Holdings Inc. (Nasdaq: GV) is a technology-driven multinational enterprise focused on AI applications, and high-tech healthcare solutions. Headquartered in Toronto, Canada, the Company operates through its subsidiaries across North America and Asia, driving technological advancement, cross-border innovation, and global health transformation.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will”, “expects”, “anticipates”, “future”, “intends”, “plans”, “believes”, “estimates”, “target”, “going forward”, “outlook”, “objective” and similar terms. Such statements are based upon management's current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and which are beyond GV's control, which may cause GV's actual results, performance or achievements (including the RMB/USD value of its anticipated benefit to GV as described herein) to differ materially and in an adverse manner from anticipated results contained or implied in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in GV's filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. GV does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.

Contacts:

Visionary Holdings Inc.
Investor Relations
Email: IR@visionary.holdings


FAQ**

How does Visionary Holdings Inc. (GV) plan to leverage its partnership with Qingdao Xihai Rongke Enterprise Operation Management Co., Ltd. to position itself against competitors like Goldfield Corporation in the anti-aging sector?

Visionary Holdings Inc. plans to leverage its partnership with Qingdao Xihai Rongke Enterprise Operation Management Co., Ltd. by enhancing product innovation and distribution strategies to gain a competitive edge against rivals like Goldfield Corporation in the anti-aging sector.

What specific steps will Visionary Holdings Inc. (GV) take to ensure the successful establishment of the GV China Anti-Aging Research Center, and how will its outcomes compare to industry benchmarks set by companies such as Goldfield Corporation?

Visionary Holdings Inc. will implement a strategic plan focusing on local partnerships, cutting-edge technology, regulatory compliance, and comprehensive research protocols for the GV China Anti-Aging Research Center to achieve superior outcomes compared to Goldfield Corporation's benchmarks.

With an initial investment framework in place, how does Visionary Holdings Inc. (GV) intend to address potential risks and challenges in the Qingdao project that other firms like Goldfield Corporation may face?

Visionary Holdings Inc. (GV) plans to mitigate potential risks and challenges in the Qingdao project through a robust risk assessment framework, adaptive project management strategies, and strategic partnerships, distinguishing itself from competitors like Goldfield Corporation.

Can Visionary Holdings Inc. (GV) provide insights on how the strategic investment for its Qingdao project might impact its long-term market positioning relative to competitors like Goldfield Corporation in the global healthcare landscape?

Visionary Holdings Inc.'s strategic investment in the Qingdao project could enhance its competitive advantage by improving operational efficiencies and expanding its market reach, thus positioning it favorably against rivals like Goldfield Corporation in the global healthcare landscape.

**MWN-AI FAQ is based on asking OpenAI questions about Goldfield Corporation (The) (NASDAQ: GV).

Goldfield Corporation (The)

NASDAQ: GV

GV Trading

-7.86% G/L:

$0.258 Last:

7,044,636 Volume:

$0.23 Open:

mwn-alerts Ad 300

GV Latest News

GV Stock Data

$6,869,001
3,955,440
N/A
3
N/A
Education
Consumer Staples
CA
Markham

Subscribe to Our Newsletter

Link Market Wire News to Your X Account

Download The Market Wire News App